SG11202005880XA - Heavy chain antibodies binding to cd22 - Google Patents
Heavy chain antibodies binding to cd22Info
- Publication number
- SG11202005880XA SG11202005880XA SG11202005880XA SG11202005880XA SG11202005880XA SG 11202005880X A SG11202005880X A SG 11202005880XA SG 11202005880X A SG11202005880X A SG 11202005880XA SG 11202005880X A SG11202005880X A SG 11202005880XA SG 11202005880X A SG11202005880X A SG 11202005880XA
- Authority
- SG
- Singapore
- Prior art keywords
- heavy chain
- chain antibodies
- antibodies binding
- binding
- heavy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762609759P | 2017-12-22 | 2017-12-22 | |
| PCT/US2018/067299 WO2019126756A1 (en) | 2017-12-22 | 2018-12-21 | Heavy chain antibodies binding to cd22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202005880XA true SG11202005880XA (en) | 2020-07-29 |
Family
ID=65041936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202005880XA SG11202005880XA (en) | 2017-12-22 | 2018-12-21 | Heavy chain antibodies binding to cd22 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11873336B2 (es) |
| EP (1) | EP3728319A1 (es) |
| JP (2) | JP7486421B2 (es) |
| KR (1) | KR20200104342A (es) |
| CN (1) | CN111683966B (es) |
| AU (1) | AU2018392088A1 (es) |
| BR (1) | BR112020012554A2 (es) |
| CA (1) | CA3086665A1 (es) |
| CL (2) | CL2020001703A1 (es) |
| CO (1) | CO2020008925A2 (es) |
| CR (1) | CR20200322A (es) |
| EA (1) | EA202091557A1 (es) |
| EC (1) | ECSP20042489A (es) |
| IL (1) | IL275498A (es) |
| JO (1) | JOP20200157A1 (es) |
| MX (1) | MX2020006494A (es) |
| NI (1) | NI202000050A (es) |
| PE (1) | PE20201171A1 (es) |
| PH (1) | PH12020550964A1 (es) |
| SG (1) | SG11202005880XA (es) |
| WO (1) | WO2019126756A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230129583A (ko) | 2016-06-21 | 2023-09-08 | 테네오바이오, 인코포레이티드 | Cd3 결합 항체 |
| CN109843325B (zh) | 2016-09-14 | 2023-10-03 | 特尼奥生物股份有限公司 | Cd3结合抗体 |
| EP3642236A1 (en) | 2017-06-20 | 2020-04-29 | TeneoOne, Inc. | Anti-bcma heavy chain-only antibodies |
| JP7486421B2 (ja) | 2017-12-22 | 2024-05-17 | テネオバイオ， インコーポレイテッド | Ｃｄ２２に結合する重鎖抗体 |
| JOP20210323A1 (ar) * | 2019-06-14 | 2023-01-30 | Teneobio Inc | ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3 |
| KR20210143097A (ko) * | 2020-05-19 | 2021-11-26 | (주)이노베이션바이오 | Cd22에 특이적인 항체 및 이의 용도 |
| CN116323948A (zh) * | 2020-07-16 | 2023-06-23 | 南京传奇生物科技有限公司 | Cd22结合分子及其用途 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| CN100390288C (zh) | 2000-04-11 | 2008-05-28 | 杰南技术公司 | 多价抗体及其应用 |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| NZ538996A (en) | 2002-10-31 | 2008-04-30 | Genentech Inc | Methods and compositions for increasing antibody production |
| EP1585768A2 (en) | 2003-01-23 | 2005-10-19 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| MX2007000921A (es) | 2004-07-22 | 2007-11-09 | Univ Erasmus Medical Ct | Moleculas de union. |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP3461842A1 (en) | 2007-04-03 | 2019-04-03 | Amgen Research (Munich) GmbH | Cross-species-specific binding domain |
| US8703485B2 (en) | 2007-06-01 | 2014-04-22 | Omt, Inc. | Germ cells having inactivated endogenous immunoglobulin genes, and transgenic animals derived therefrom |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| US8207306B2 (en) | 2008-09-19 | 2012-06-26 | Medimmune, Llc | Targeted binding agents directed to sonic hedgehog homolog and uses thereof |
| RS54900B1 (sr) | 2008-10-01 | 2016-10-31 | Amgen Res (Munich) Gmbh | Interspecijski specifično psmaxcd3 bispecifično jednolančano antitelo |
| WO2010104949A2 (en) | 2009-03-10 | 2010-09-16 | Biogen Idec Ma Inc. | Anti-bcma antibodies |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| HUE029785T2 (en) | 2010-02-08 | 2017-04-28 | Regeneron Pharma | Common mouse light chain |
| TWI653333B (zh) | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| JP2014500879A (ja) | 2010-11-16 | 2014-01-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法 |
| CN103619876A (zh) | 2011-03-10 | 2014-03-05 | Hco抗体股份有限公司 | 双特异性三链抗体样分子 |
| WO2012122512A1 (en) | 2011-03-10 | 2012-09-13 | Hco Antibody, Inc. | Recombinant production of mixtures of single chain antibodies |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| MX366813B (es) | 2012-04-20 | 2019-07-25 | Aptevo Res & Development Llc | Polipeptidos de enlace cd3. |
| AU2013251482B2 (en) | 2012-04-26 | 2018-01-04 | Bioatla Llc | Anti-CD22 antibodies |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| LT2931030T (lt) | 2012-12-14 | 2020-11-10 | Open Monoclonal Technology, Inc. | Polinukleotidai, koduojantys graužikų antikūnus su žmogaus idiotipais, ir juos apimantys gyvūnai |
| WO2014122144A1 (en) | 2013-02-05 | 2014-08-14 | Engmab Ag | BISPECIFIC ANTIBODIES AGAINST CD3ε AND BCMA |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | Moléculas de unión para bcma y cd3 |
| WO2015095412A1 (en) | 2013-12-19 | 2015-06-25 | Zhong Wang | Bispecific antibody with two single-domain antigen-binding fragments |
| EP3105252B1 (en) | 2014-02-12 | 2019-07-24 | Michael Uhlin | Bispecific antibodies for use in stem cell transplantation |
| US9139649B2 (en) | 2014-02-25 | 2015-09-22 | Immunomedics, Inc. | Humanized anti-CD22 antibody |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| TWI750110B (zh) | 2014-07-21 | 2021-12-21 | 瑞士商諾華公司 | 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症 |
| CN107108738A (zh) | 2014-07-25 | 2017-08-29 | 西托姆克斯治疗公司 | 抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法 |
| EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| JP7164949B2 (ja) | 2014-11-20 | 2022-11-02 | エフ．ホフマン－ラ ロシュ アーゲー | 共通軽鎖および使用方法 |
| CN104710528B (zh) * | 2015-03-13 | 2019-02-15 | 西北农林科技大学 | 一种特异性结合PRRS病毒非结构蛋白Nsp9纳米抗体及其应用 |
| CR20180420A (es) | 2016-02-03 | 2018-12-05 | Amgen Inc | Constructos de anticuerpo biespecíficos para bcma y cd3 que se ligan a células t |
| KR20230129583A (ko) | 2016-06-21 | 2023-09-08 | 테네오바이오, 인코포레이티드 | Cd3 결합 항체 |
| MX2019002256A (es) | 2016-08-24 | 2019-10-09 | Teneobio Inc | Animales transgenicos no humanos que producen anticuerpos modificados solo de cadena pesada. |
| CN109843325B (zh) | 2016-09-14 | 2023-10-03 | 特尼奥生物股份有限公司 | Cd3结合抗体 |
| KR102633423B1 (ko) | 2016-12-21 | 2024-02-06 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
| EP3642236A1 (en) | 2017-06-20 | 2020-04-29 | TeneoOne, Inc. | Anti-bcma heavy chain-only antibodies |
| CN117866097A (zh) | 2017-06-20 | 2024-04-12 | 特尼奥生物股份有限公司 | 仅有重链的抗bcma抗体 |
| AU2018291128A1 (en) | 2017-06-30 | 2020-01-23 | Teneobio, Inc. | Anti-B-cell maturation antigen chimeric antigen receptors with human domains |
| EP3681908A1 (en) | 2017-09-13 | 2020-07-22 | Teneobio, Inc. | Heavy chain antibodies binding to ectoenzymes |
| JP7486421B2 (ja) | 2017-12-22 | 2024-05-17 | テネオバイオ， インコーポレイテッド | Ｃｄ２２に結合する重鎖抗体 |
| JP2021508479A (ja) | 2017-12-27 | 2021-03-11 | テネオバイオ， インコーポレイテッド | ヘテロ二量体特異的抗体上のｃｄ３デルタ及びｃｄ３イプシロン |
| SG11202011597RA (en) | 2018-07-20 | 2020-12-30 | Teneobio Inc | Heavy chain antibodies binding to cd19 |
| SG11202102713TA (en) | 2018-09-21 | 2021-04-29 | Teneobio Inc | Methods for purifying heterodimeric, multispecific antibodies |
| CA3100232A1 (en) | 2018-10-26 | 2020-04-30 | Teneobio, Inc. | Heavy chain antibodies binding to cd38 |
| AU2020252556A1 (en) | 2019-04-05 | 2021-10-21 | Teneobio, Inc. | Heavy chain antibodies binding to PSMA |
| JOP20210323A1 (ar) | 2019-06-14 | 2023-01-30 | Teneobio Inc | ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3 |
| IL293751A (en) | 2019-12-18 | 2022-08-01 | Teneofour Inc | Heavy chain antibodies that bind to cd38 |
| UY39191A (es) | 2020-04-29 | 2021-11-30 | Teneobio Inc | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas |
| WO2021222616A1 (en) | 2020-04-29 | 2021-11-04 | Teneobio, Inc. | Methods of treating multiple myeloma |
| CN116472049A (zh) | 2020-06-30 | 2023-07-21 | 特尼奥生物股份有限公司 | 与bcma结合的多特异性抗体 |
| TW202233684A (zh) | 2020-11-18 | 2022-09-01 | 美商泰尼歐生物公司 | 結合於葉酸受體α之重鏈抗體 |
| KR20230148828A (ko) | 2021-02-25 | 2023-10-25 | 테네오바이오, 인코포레이티드 | 항-psma 항체 및 car-t 구조 |
| CN116917327A (zh) | 2021-02-26 | 2023-10-20 | 特尼奥生物股份有限公司 | 抗muc1-c抗体及car-t结构 |
| TW202304994A (zh) | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | 促效性抗ｉｌ－２ｒ抗體及使用方法 |
| WO2022216864A1 (en) | 2021-04-06 | 2022-10-13 | Teneobio, Inc. | Anti-cd19 antibodies and car-t structures |
| WO2022221698A1 (en) | 2021-04-16 | 2022-10-20 | Teneobio, Inc. | Anti-cd20 antibodies and car-t structures |
| WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
| WO2023004197A1 (en) | 2021-07-23 | 2023-01-26 | Teneoten, Inc. | Heavy chain antibodies binding to hepatitis b surface antigen |
-
2018
- 2018-12-21 JP JP2020534858A patent/JP7486421B2/ja active Active
- 2018-12-21 US US16/956,502 patent/US11873336B2/en active Active
- 2018-12-21 AU AU2018392088A patent/AU2018392088A1/en active Pending
- 2018-12-21 EP EP18836782.5A patent/EP3728319A1/en active Pending
- 2018-12-21 BR BR112020012554-7A patent/BR112020012554A2/pt active Search and Examination
- 2018-12-21 JO JOP/2020/0157A patent/JOP20200157A1/ar unknown
- 2018-12-21 CA CA3086665A patent/CA3086665A1/en active Pending
- 2018-12-21 SG SG11202005880XA patent/SG11202005880XA/en unknown
- 2018-12-21 CN CN201880083056.4A patent/CN111683966B/zh active Active
- 2018-12-21 KR KR1020207021048A patent/KR20200104342A/ko active Search and Examination
- 2018-12-21 MX MX2020006494A patent/MX2020006494A/es unknown
- 2018-12-21 CR CR20200322A patent/CR20200322A/es unknown
- 2018-12-21 EA EA202091557A patent/EA202091557A1/ru unknown
- 2018-12-21 WO PCT/US2018/067299 patent/WO2019126756A1/en active Application Filing
- 2018-12-21 PE PE2020000809A patent/PE20201171A1/es unknown
-
2020
- 2020-06-18 IL IL275498A patent/IL275498A/en unknown
- 2020-06-20 CL CL2020001703A patent/CL2020001703A1/es unknown
- 2020-06-22 NI NI202000050A patent/NI202000050A/es unknown
- 2020-06-22 PH PH12020550964A patent/PH12020550964A1/en unknown
- 2020-07-21 CO CONC2020/0008925A patent/CO2020008925A2/es unknown
- 2020-07-22 EC ECSENADI202042489A patent/ECSP20042489A/es unknown
-
2022
- 2022-08-18 CL CL2022002247A patent/CL2022002247A1/es unknown
-
2023
- 2023-12-07 US US18/532,880 patent/US20240117046A1/en active Pending
-
2024
- 2024-02-05 JP JP2024015399A patent/JP2024062992A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020124188A (ru) | 2022-01-24 |
| EA202091557A1 (ru) | 2020-11-18 |
| PE20201171A1 (es) | 2020-10-28 |
| US20210095022A1 (en) | 2021-04-01 |
| CO2020008925A2 (es) | 2020-10-30 |
| CN111683966B (zh) | 2023-07-11 |
| US20240117046A1 (en) | 2024-04-11 |
| JP7486421B2 (ja) | 2024-05-17 |
| CA3086665A1 (en) | 2019-06-27 |
| CL2020001703A1 (es) | 2020-11-06 |
| US11873336B2 (en) | 2024-01-16 |
| KR20200104342A (ko) | 2020-09-03 |
| WO2019126756A1 (en) | 2019-06-27 |
| EP3728319A1 (en) | 2020-10-28 |
| CR20200322A (es) | 2021-01-12 |
| IL275498A (en) | 2020-08-31 |
| CL2022002247A1 (es) | 2023-02-24 |
| JOP20200157A1 (ar) | 2022-10-30 |
| NI202000050A (es) | 2020-12-04 |
| JP2024062992A (ja) | 2024-05-10 |
| MX2020006494A (es) | 2020-11-24 |
| CN111683966A (zh) | 2020-09-18 |
| AU2018392088A2 (en) | 2020-08-27 |
| JP2021506325A (ja) | 2021-02-22 |
| BR112020012554A2 (pt) | 2020-11-24 |
| WO2019126756A9 (en) | 2019-10-17 |
| ECSP20042489A (es) | 2020-11-30 |
| AU2018392088A1 (en) | 2020-08-13 |
| PH12020550964A1 (en) | 2021-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276537A (en) | Antibodies bind to GPRC5D | |
| HK1252863A1 (zh) | 結合cd22的抗體分子 | |
| IL261188A (en) | Antibodies against tigit | |
| ZA201803669B (en) | Antibodies specifically binding pd-1 and their uses | |
| IL274370A (en) | Single-region antibodies that bind CD137 | |
| IL275498A (en) | Heavy chain antibodies that bind CD22 | |
| IL287613A (en) | Antibodies that bind gprc5d | |
| IL271194A (en) | Antibodies against bcma containing only heavy chains | |
| IL279010A (en) | Heavy chain antibodies that bind to CD19 | |
| HK1256300A1 (zh) | 特異性地結合至tl1a的抗體 | |
| IL286398A (en) | Heavy chain antibodies that bind to psma | |
| ZA201905341B (en) | Antibodies specifically binding to human il-1r7 | |
| IL282590A (en) | Heavy chain antibodies that bind to CD38 | |
| IL273235A (en) | Heavy chain antibodies that bind to ectoenzymes | |
| IL269394A (en) | Antibodies bind to STEAP-1 | |
| HK1253947A1 (zh) | 僅有重鏈的抗ang-2抗體 | |
| HK1254093A1 (zh) | 僅有重鏈的pdgf抗體 | |
| GB201709379D0 (en) | Humanised ADAMTS13 binding antibodies | |
| GB201715149D0 (en) | IL-ß binding antibody | |
| GB201718734D0 (en) | Single domain antibodies that bind to CD137 |